BACKGROUND
• Heritable cardiac diseases are primarily caused by mutations of genes that encode for ion channels or their regulators 1 .
• A positive genetic test allows to confirm the diagnosis or to identify silent carriers within families. In certain conditions, the identification of a mutation has a further impact on risk stratification and treatment 2 .
• Routine management of families with cardiomyopathies and channelopathies at risk of sudden cardiac death (SCD) includes periodic lifetime clinical screening of family members.
• Limitations in availability and costs have meant genetic testing not to be considered in routine practice for many families. 
OBJECTIVES

METHODS
• A 3-year budget impact analysis was carried out based on international sources of epidemiological and healthcare resource utilization data; local costs; market share estimates, and expert opinion.
• Two scenarios were compared: SCENARIO 1: current clinical practice (clinical screening alone, without genetic testing) vs. SCENARIO 2: alternative clinical practice (clinical screening with genetic testing).
• The perspective adopted was that of the Spanish National Healthcare System (NHS). Only direct costs associated to diagnosis, treatment and follow-up of patients were taken into account. All costs referred to €,2012.
Figure 1: Model scheme
Target population • The target population at risk of SCD was calculated for the Spanish population of 1 to 90 years of age.
• To determine the size of the index cases population the annual incidence of the 5 cardiopathies was considered. Based on these figures, it was calculated the number of patients presenting minor or major symptoms, being asymptomatic, or having a SCD. Minor symptoms included palpitations, dizziness, fatigue, chest pain, dyspnea while major symptoms encompassed syncope and an aborted SCD. Data were derived from relevant trials and registries, complemented with experts' opinion in case of unavailable data. To input each year new cases, the number of index cases was yearly updated.
• The number of index cases resulting each year was multiplied by 4 (expert opinion) to determine the number of first-degree family members potentially affected by the hereditary cardiopathy.
Figure 2: Calculation of the target population
• The target population at risk of SCD was estimated on 25,220 patients for the first year; 26,352 for the second year, and 26,340 for the third year.
Clinical screening strategies
• It was assumed that clinical screening alone has a given probability of identifying patients with each studied cardiopathy (expert opinion), and that genetic testing has a probability of identifying a mutation in index cases (according to relevant trials and registries). The prevalence of mutation in first-degree family members was 50% (autosomal dominant inheritance). • The economic impact of introducing the genetic test for all five cardiopathies would imply an additional cost of € 315,168, € 540,549, and € 733,578 each subsequent year, respectively, to the National Health System (Table 1 ).
• The highest costs of managing patients at risk of SCD due to hereditary cardiopathies corresponds to HCM individuals followed by ARVC, LQTS, CPTV and BrS patients in both scenarios. (Table 2) .
• Conducting genetic tests in index cases represents the highest costs compared to diagnosing first-degree family members
Table 2: Proportion of total costs corresponding to index cases and first-degree relatives
• Introduction of genetic testing in clinical practice would imply an increase in diagnosis costs compared to current practice, and a decrease in treatment and follow-up costs.
Figure 4: Cumulative mean cost
• As the number of index cases increases each year, the reduction in the costs of treatment and follow-up progressively compensates the increase on diagnosis costs (Table 3) . 
RESOURCES USE AND COSTS: diagnosis, treatment and follow-up
SCENARIO 1
Current clinical practice
Clinical screening without genetic testing
OUTPUTS
Cost of 5 cardiopathies in:
• index cases
• first-degree family members
SCENARIO 2
Alternative practice Clinical screening and genetic testing
OUTPUTS
Cost of 5 cardiopathies in:
• index cases 
